DO NOT PRESCRIBE (DNP): NICE TA227: Lung cancer (non small-cell, advanced or metastatic maintenance treatment). Erlotinib (monotherapy) not recommended after platinum chemotherapy (decision date - July 2011)
RED:1,2,3 NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) Erlotinib – a recommended first-line option in locally advanced or metastatic non-small-cell lung cancer (decision date - July 2012)
RED:1,2,3 NICE TA374: for treating non small cell lung cancer that has progressed after prior chemotherapy. (Decision date - January 2016)
NHS England drug. To be used in line with NHS England commissioning intentions